The Role of Event-Based Biosurveillance in Biodefense

Hartley, David; Mui, Wai-Ling; Corley, Courtney D.

doi:10.1007/978-3-030-03053-7_3

Cited by 2 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These indicators were Incidence Rate(IR), Capacity(CP), Timeliness(TL), and Completeness(CO). Indicators were assigned quantitative 'scores,' or numerical grades, to normalize collected data and ensure uniform analysis and scoring per traditional biosurveillance methodological practices [12] (i.e., categorization of events and their elements into specific indicators that provide context to an event of interest). IR and CP indicators were further delineated into attributes.…”

Section: Integrated Analytic Indicators and Attributesmentioning

confidence: 99%

“…These populations are often at the greatest risk of infectious diseases like TB and could benefit greatly from having access to novel therapeutics and interventions. Clinical trials are integral to improving and sustaining equity related to high burden of disease, yet <20% of trials are conducted in LMICs or developing countries [12]. In addition to the individual and public health benefits, sites that serve these underrepresented populations may also have an opportunity to enhance their capacity and capabilities through the conduct of a clinical trial.…”

Section: Plos Global Public Healthmentioning

confidence: 99%

“…It is well-established that improving equity in clinical trials is necessary both in terms of ensuring that the most vulnerable populations who often experience the greatest burden of disease have access to clinical trials and that a diversity of populations are represented in clinical trials [17][18][19]. In addition, the lack of accessibility and under-representation of LMICs in global clinical trials contributes to the continued overall health inequities in these countries [12]. While there is increasing discussion on the importance of improving equity and accessibility of clinical trials to under-represented populations, the practical implementation of this remains a challenge.…”

Section: Plos Global Public Healthmentioning

confidence: 99%

See 2 more Smart Citations

Data-driven epidemiologic approach to conducting site feasibility for a global phase III tuberculosis vaccine clinical trial

Mui,

Parekh,

Tseng

et al. 2023

PLOS Glob Public Health

Self Cite

View full text Add to dashboard Cite

An efficacious tuberculosis (TB) vaccine is critical to reducing the global burden of TB. TB vaccine trials require the identification of multiple sites globally that have both a high incidence of TB and the capacity to conduct a clinical trial. To expand the diversity of potential phase III TB vaccine trial sites to be considered for inclusion, we describe a novel epidemiologic method that incorporates approaches from a variety of public health practices. Our approach incorporates analytic methodology to enable quantification and validation of qualitative information from disparate data sources, and epidemiologic analysis to systematically assess site-specific TB epidemiology. The integration of robust data-driven practices, and more quantitatively focused analysis, allowed for the objective evaluation of sites, which resulted in the identification of sites and catchment areas with high TB burden that may not have been previously considered. This suggests that an integrated epidemiologic methodology, not traditionally utilized for clinical trial site evaluations, could be integrated into site feasibility assessments as it results in more rapid site identification and reduces unintended bias.

show abstract

Section: Integrated Analytic Indicators and Attributesmentioning

confidence: 99%

Section: Plos Global Public Healthmentioning

confidence: 99%